Full-Time

Principal Roivant Health

Roivant Sciences

Roivant Sciences

201-500 employees

Biopharmaceutical company developing RNA therapeutics

Compensation Overview

$130k - $220k/yr

+ Discretionary Bonus + Equity

New York, NY, USA

In Person

Category
Business & Strategy (1)
Requirements
  • Exceptional academic background
  • Proven ability to thrive in entrepreneurial environments, managing multiple roles
  • Track record of taking on significant responsibility in fast-paced organizations
  • Strong executive-level communication and analytical skills
  • Experience building ventures or products in healthcare or life sciences technology
Responsibilities
  • Lead early-stage ideation by identifying and evaluating potential opportunities based on key success factors, such as time to market, Roivant’s strategic advantages, validation pathway, and market potential
  • Lead structured evaluations to de-risk incubations, assessing markets, competitors, product landscapes, and technology
  • Oversee initial company building, including product development, business development, operations, and fundraising
  • Recruit and develop leadership teams for new Vants
  • Ensure ongoing success of incubated ventures through board participation and oversight
  • Lead or support external financing efforts for new Vants

Roivant Sciences develops and delivers medicines, with a focus on genetic disorders and RNA therapeutics, using in-house R&D plus strategic partnerships. Its subsidiary Genevant uses proprietary delivery platforms to create RNA-based treatments, including mRNA, RNA interference, and gene editing. Revenue comes from developing drug candidates, licensing deals, partnerships, and selling approved drugs, leveraging collaborations to accelerate the pipeline. The goal is to bring effective medicines to patients faster and more efficiently by combining technology platforms with strategic alliances.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Genevant secures $2.25B settlement from Moderna, $950M upfront July 2026.
  • VTAMA generates revenue for plaque psoriasis; Dermavant expands dermatology.
  • Pulmovant in-licenses mosliciguat from Bayer for pulmonary hypertension.

What critics are saying

  • Pfizer dominates mRNA, eroding Genevant's RNAi market share immediately.
  • Brepocitinib Phase 3 fails FDA efficacy, destroying $500M pipeline value.
  • Bayer terminates Pulmovant after Phase 2 failures, cutting 30% revenue.

What makes Roivant Sciences unique

  • Roivant builds Vants as agile subsidiaries for focused drug development.
  • Genevant pioneers RNA therapeutics using mRNA, RNAi, and gene editing.
  • Datavant integrates data tools to accelerate clinical trials and evidence.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
Stock Titan
Dec 11th, 2025
Immunovant prices $550M stock offering to fund IMVT-1402 Graves' disease launch

Immunovant has priced an underwritten common stock offering of 26.2 million shares at $21.00 per share, raising approximately $550 million in gross proceeds. The company expects existing cash plus the proceeds to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves' disease. Roivant Sciences, Immunovant's controlling stockholder, has agreed to purchase shares in the offering. Leerink Partners is acting as sole underwriter. The offering is expected to close on or about 12 December 2025, subject to customary closing conditions. The shares are being offered pursuant to an automatic registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

PsiThera
Dec 10th, 2025
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets - PsiThera

Watertown, MA, December 10, 2025 — PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital…

GlobeNewswire
Sep 11th, 2025
Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Earning a spot means that Roivant is one of the best companies to work for in the country.

Investing.com
Feb 24th, 2025
Roivant Sciences president Eric Venker sells $1.07 million in shares

Jennifer Humes has been appointed to succeed Kumar as the new Principal Accounting Officer for Roivant Sciences Ltd. and Chief Accounting Officer for Roivant Sciences, Inc.

FinSMEs
Feb 3rd, 2025
Zest Health Raises $13M in Funding

Zest Health, a NYC-based virtual care company focused on treating patients with inflammatory skin diseases, raised $13M in Seed funding